NVAX•benzinga•
For 2025, Novavax Expects To Achieve Adjusted Licensing, Royalties And Other Revenue Of Between $300M-$350M, Ended Full Year 2024 With Over $1B In Cash And Accounts Receivables
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 27, 2025 by benzinga